So great to have the Kinoxis research team together for lunch in one place today.

Kinoxis is a proud spin out of the University of Sydney - a great model, supported in our case by the team ⁦UniseedFund⁩ theaustralian.com.au/higher-educati…

The use of opioids to treat acute and chronic pain contributed to approximately 10.3 million people age 12 years and older in the U.S. who misused opioids in 2018. The #nihHEALinitiative is working to end the national opioid public health crisis. loom.ly/_rmi-uE

Australia's opioid crisis: Deaths rise as companies encourage doctors to prescribe theage.com.au/national/austr… via The Age

@Kinoxis_tx is pleased to be sharing our story at the Emergence2020 event in Sydney today. Thanks Wholesale Investor for a great event!

Great to be working more closely with BioCurate on biotech projects at the @unimelb . C. Glenn Begley #seedingthefuture theaustralian.com.au/higher-educati…

How the pandemic is making the opioid crisis worse newsweek.com/2020/08/14/how…

As 2020 comes to a close, Kinoxis is pleased to announce the completion of a $5m funding round from existing shareholders. UniseedFund University of Sydney linkedin.com/pulse/kinoxis-…

A great resource published recently by some of our collaborators at University of Sydney. Targeting the oxytocin receptor in the brain holds so much promise for many neurological disorders & @Kinoxis_tx is making great progress on several promising therapeutic candidates.

Well done Associate Professor Michael Bowen Michael Bowen of Brain & Mind Centre and @Kinoxis_tx, for being award the Prize for New Innovators in the 2021 Prime Minister’s Prizes for Science. Further motivation for our incredible team! ScienceGovAu #pmprizes UniseedFund

Chapter 10 in the new book "Oxytocin" is led by co-editor Tristan Reekie and reviews all the molecules reported to be active in the oxytocin system link.springer.com/protocol/10.10… Editors: E. Werry, Tristan Reekie Michael Kassiou

Overdose Deaths Reached Record High as the Pandemic Spread nytimes.com/2021/11/17/hea…

The Opioid crisis remains a key challenge for the US and a reminder to the Kinoxis team of the importance of our work as we continue development of new treatment options. Opioid crisis: Congress and Biden suggest radical change to War on Drugs approach finance.yahoo.com/news/opioid-cr…

Great to get the Kinoxis team together for a Christmas catch up. Michael Bowen Michael Kassiou Iain McGregor

It’s a proud day for @Kinoxis_tx, as we announce a partnership with Boehringer Ingelheim to develop oxytocin-targeting therapeutics to help people with #neuropsychiatric disorders. Read about our partnership and the exciting science behind it here: t.ly/dgnb

We are joining forces with @Kinoxis_tx to develop first-in-class precision psychiatry treatments to improve the quality of life of people living with neuropsychiatric disorders. Learn more: bit.ly/419FvTY #PrecisionPsychiatry #MentalHealth

The approval of OPVEE today by the FDA is another tool in the battle against the opioid crisis. The development, approval and availability of new treatment options is an essential part of the solution to control the devastating harm caused from opioid use disorder.

.@Kinoxis_tx is excited to announce US$3.6m grant from NIDAnews to fund the Phase 1 trial for lead drug #KNX100, targeted at addressing opioid withdrawal. Learn more about what this means for Kinoxis, KNX100 and those battling opioids: tinyurl.com/2p99h294 #biotech #science

@Kinoxis_tx is pleased to share that our CEO Hugh Alsop has been recognised as the CEO of the Year by Brooker Consulting, for his significant contribution to the life sciences industry. Congratulations to Hugh and all other award recipients! #leadershipaward

@Kinoxis_tx is pleased to share that $14.5m in funding has been raised to support Phase 2 programs for lead drug asset KNX100. We would like to thank key investors for sharing and supporting our vision in treating #dementia and #substanceusedisorder. More: kinoxistherapeutics.com/wp-content/upl…